· Event impact

Trump Executive Order Accelerates Psychedelic Drug Approvals, Boosting Enveric Biosciences

Type: Geopolitical ShiftConfidence: 1Verified: unverified
President Trump issued an executive order directing federal agencies to expedite approval timelines for psychedelic-based treatments and committed $50 million to ibogaine research. This action caused Enveric Biosciences (ENVB), a company in the psychedelic drug space, to surge over 106% in premarket trading.

Transmission path

Government executive order -> Regulatory acceleration -> Increased market access for specific drug types -> Boost to related biotech companies.

Extended read

President Trump has signed an executive order instructing federal agencies to accelerate the approval process for psychedelic-based treatments. Concurrently, the administration has pledged $50 million towards ibogaine research. This policy shift is a significant development for the nascent psychedelic therapeutics industry. In immediate market reaction, Enveric Biosciences (ENVB), a company operating in this sector, saw its stock price surge by over 106% in premarket trading, indicating strong investor confidence in the potential for faster market access and increased research funding for these treatments.

Exposed assets

ENVB

Countries: United States

Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →